drugset / Trial / NCT00799331

Exploratory Study to Assess the Pharmacokinetics of AZD5985

NCT00799331 ↗

Phase 1 Completed 32 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindBasic science

Summary

The aim of this exploratory study is to assess the pharmacokinetics of increasing oral doses of AZD5985 in healthy male volunteers

Timeline

Start
2008-11
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5985 Unknown 4 mg Oral

Indications

No indication recorded.